Literature DB >> 121055

Purification and partial characterization of plasminogen activator from human uterine tissue.

D C Rijken, G Wijngaards, M Zaal-de Jong, J Welbergen.   

Abstract

A procedure was developed for the purification of a plasminogen activator from human uterine tissue. It involves six consecutive steps: (1) extraction of the plasminogen activator from delipidated uterine tissue with 0.3 M potassium acetate buffer, pH 4.2; (2) ammonium sulphate precipitation; (3) zinc chelate-agarose chromatography; (4) n-butyl-agarose chromatography; (5) concanavalin A-agarose chromatography; and (6) gel filtration on Sephadex G-150. The specific activity of the final plasminogen activator preparation was increased by a factor 4500 as compared with the crude extract. The purified plasminogen activator showed a strong tendency to adsorb to surfaces. This could be effectively prevented by Tween-80. The molecular weight of the plasminogen activator was 64 000 as estimated by gel filtration in 1.0 M NaCl and 69 000 as estimated by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulphate. The plasminogen activator consisted of two chains (molecular weights 31 000 and 38 000) connected by disulphide bridges. The smallest chain contained the serine residue of the active site as deduced from the incorporation of the tritium label of [3H]diisopropylphosphofluoridate.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 121055     DOI: 10.1016/0005-2795(79)90205-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  29 in total

1.  The Emergence of Thrombocardiology.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1994       Impact factor: 2.300

2.  Is thrombolysis alone the best therapy for acute myocardial infarction? Current status and emerging strategies.

Authors:  P Golino; J T Willerson
Journal:  Tex Heart Inst J       Date:  1991

3.  Clearance of the heavy and light polypeptide chains of human tissue-type plasminogen activator in rats.

Authors:  D C Rijken; J J Emeis
Journal:  Biochem J       Date:  1986-09-15       Impact factor: 3.857

4.  The evolution of recombinant thrombolytics: Current status and future directions.

Authors:  Yogender Pal Khasa
Journal:  Bioengineered       Date:  2016-10-03       Impact factor: 3.269

5.  Tissue-type plasminogen activator. Therapeutic potential in thrombotic disease states.

Authors:  D Collen
Journal:  Drugs       Date:  1986-01       Impact factor: 9.546

6.  Ultrasound-enhanced rt-PA thrombolysis in an ex vivo porcine carotid artery model.

Authors:  Kathryn E Hitchcock; Nikolas M Ivancevich; Kevin J Haworth; Danielle N Caudell Stamper; Deborah C Vela; Jonathan T Sutton; Gail J Pyne-Geithman; Christy K Holland
Journal:  Ultrasound Med Biol       Date:  2011-08       Impact factor: 2.998

7.  alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder.

Authors:  C Kluft; H K Nieuwenhuis; D C Rijken; E Groeneveld; G Wijngaards; W van Berkel; G Dooijewaard; J J Sixma
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

Review 8.  Relationships among the complement, kinin, coagulation, and fibrinolytic systems.

Authors:  J S Sundsmo; D S Fair
Journal:  Springer Semin Immunopathol       Date:  1983

9.  Active site directed inhibitor used in the production of antibodies against urokinase.

Authors:  S A Cederholm-Williams; J M Marshall; H Chissic
Journal:  J Clin Pathol       Date:  1984-10       Impact factor: 3.411

10.  Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.

Authors:  C Korninger; O Matsuo; R Suy; J M Stassen; D Collen
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.